cor-por-ra-del-ic (adj): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”


Recent stories

The Third Wave’s Paul Austin Has Been Accused of Stealing Information For His Psychedelic Provider Directory

The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.

COMPASS Pathways Is Trying to Patent Psilocybin for More Mental Health Conditions Than You Can Name

News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.

Turn Off Your Mind, Relax—and Float Right-Wing?

On January 6th, 2021 at least two psychedelic heads stormed the United States Capitol. Strange as it may seem, those adhering to right-wing politics haven’t just established a beachhead in the psychedelic renaissance—they’re maneuvering to own it.

Livestream #2: Team trip reports and experiential typewriters

Weeoo weeoo livestream alert for Thursday, December 17th at 8PM ET!!. Last time we popped bottles and jammed in the comments - come hang out with us again for some reflections on 2020.

Thea Riofrancos on the Implications of Global Energy Transition and the Impacts of Lithium Extraction

Thea Riofrancos is a political scientist whose research has focused on political conflict related to extraction, energy, and infrastructure in a rapidly warming and politically unstable world. She also serves on the steering committee for Democratic Socialists of America for a Green New Deal.

The Big & Dandy List of Psychedelic-Mining-Extractive-Industry Ties

This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.

Why are so many extractive industry executives speculating on psychedelics?

Extractive industry is highly speculative by nature and firms are risk tolerant—they either “strike gold” or they don’t. When their gambles fail, psychedelic startups can take over their corporate shells to quickly go public with minimal regulatory scrutiny.

Will Extractive Industry Bring Its Disregard for Indigenous People Into The Psychedelic Industry?

A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.

As Psychedelics Enter the Mainstream, Mining Companies Look to Dig Up Profits

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

Psychedelic Media Should Stop Parroting Corporate Press Releases

When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

ATAI Life Sciences Company, EmpathBio, Dives Into MDMA Derivatives, Calls MAPS’ Approach “MDMA 1.0”

Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

DARE to Resist White Supremacy and The Police

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People

"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Field Trip Announces “World’s First” Virtual Psychedelic Therapy, But Forgets To Mention They Aren’t the First and No Psychedelics Are Involved

Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Corporadelic

A six-part series on the intersection of psychedelics and capitalism, and the early investors making it happen.


cor-por-ra-del-ic (adj): manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.

cor-por-ra-de-lia (n.): the world of people, phenomena, or items associated with corporadelic entities.

The term “corporadelic” was initially coined independently and simultaneously by Dr. Katherine MacLean (a former lead researcher and session guide for psilocybin research at Johns Hopkins University School of Medicine) and Brett Greene (co-founder emeritus of Psymposia and founder of psychedelic pharmaceutical company, Adelia Therapeutics) in 2019. Dr. MacLean defined the term as, “manifesting corporations to commodify psychedelic experiences.”


Recent stories

The Third Wave’s Paul Austin Has Been Accused of Stealing Information For His Psychedelic Provider Directory

The Third Wave copied information from Psychedelic.Support and MAPS Integration List without permission to use for its own directory.

COMPASS Pathways Is Trying to Patent Psilocybin for More Mental Health Conditions Than You Can Name

News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.

Turn Off Your Mind, Relax—and Float Right-Wing?

On January 6th, 2021 at least two psychedelic heads stormed the United States Capitol. Strange as it may seem, those adhering to right-wing politics haven’t just established a beachhead in the psychedelic renaissance—they’re maneuvering to own it.

Livestream #2: Team trip reports and experiential typewriters

Weeoo weeoo livestream alert for Thursday, December 17th at 8PM ET!!. Last time we popped bottles and jammed in the comments - come hang out with us again for some reflections on 2020.

Thea Riofrancos on the Implications of Global Energy Transition and the Impacts of Lithium Extraction

Thea Riofrancos is a political scientist whose research has focused on political conflict related to extraction, energy, and infrastructure in a rapidly warming and politically unstable world. She also serves on the steering committee for Democratic Socialists of America for a Green New Deal.

The Big & Dandy List of Psychedelic-Mining-Extractive-Industry Ties

This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.

Why are so many extractive industry executives speculating on psychedelics?

Extractive industry is highly speculative by nature and firms are risk tolerant—they either “strike gold” or they don’t. When their gambles fail, psychedelic startups can take over their corporate shells to quickly go public with minimal regulatory scrutiny.

Will Extractive Industry Bring Its Disregard for Indigenous People Into The Psychedelic Industry?

A mining firm’s conflict with Argentinian communities illustrates extractive industry’s practices and values, and raises questions about how these corporate approaches will translate into the psychedelic pharmaceutical industry.

As Psychedelics Enter the Mainstream, Mining Companies Look to Dig Up Profits

Canadian mining and exploration company AIS has had a number of executives move on to found psychedelic pharmaceutical businesses. Why? Because psychedelics are where the money’s at.

Psychedelic Media Should Stop Parroting Corporate Press Releases

When the media republishes statements from psychedelic pharmaceutical startups and their executives with little-to-no vetting, it functions as a corporate megaphone and damages the field of psychedelic science.

ATAI Life Sciences Company, EmpathBio, Dives Into MDMA Derivatives, Calls MAPS’ Approach “MDMA 1.0”

Through EmpathBio, ATAI Life Sciences says it will develop “safer” MDMA derivatives for patients with PTSD and calls the Multidisciplinary Association for Psychedelic Studies' (MAPS) approach "MDMA 1.0." MAPS' executive director, Rick Doblin, says that if that's the case, ATAI is "MDMA 0.5."

As COMPASS Pathways continues its attempts to build a psychedelic monopoly, Usona Institute keeps publishing open research

Since COMPASS Pathways filed for a controversial psilocybin patent in 2018, Usona Institute has consistently placed its research findings in the public domain.

DARE to Resist White Supremacy and The Police

American policing is a white supremacist institution that has repeatedly demonstrated the degree to which it values property over human life. Our struggles against the police are inseparably entwined with similar struggles around the world, and they cannot be disconnected from larger struggles for human rights.

MindMed’s CEO Jamon “JR” Rahn Wants Nothing To Do With Those Psychedelic Decrim People

"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

Field Trip Announces “World’s First” Virtual Psychedelic Therapy, But Forgets To Mention They Aren’t the First and No Psychedelics Are Involved

Field Trip Ventures leads the charge to use “psychedelic” as a marketing buzzword for any kind of niche therapy.

Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think

Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”

Amidst Pandemic, Psychedelic Investor Christian Angermayer Can’t Imagine Life Beyond Capitalism

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

“Flattening The Curve is Complete BS”: Pandemic Advice From Psychedelic Investor Christian Angermayer

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

Dear Psychedelic Researchers

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

Calm Down. What’s the Worst Thing That the Wellness Industry Could Do to Psychedelics?

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.